UK

In December 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (endobronchial nerve ablation for chronic obstructive pulmonary disease and transanal total mesorectal excision for rectal cancer), two new Medical Technologies Guidance (ClearGuard HD antimicrobial barrier caps, and Endo-SPONGE for treating low rectal anastomotic leak), and one new Medtech Innovation Briefings (FreeO2 automatic oxygen titration). Also, one new clinical guideline was published, and five were updated.

In December 2021, NHSX announced that the new elective recovery tech fund would support over 400 innovative digital technologies. The fund has been established to help NHS organizations accelerate the uptake of digitally supported elective care. Up to £250 million has been made available to Integrated Care Systems as a part of a £700 million Targeted Investment Fund intended to speed up elective recovery and tackle waiting lists.

On December 17, 2021, NHS Digital released HRG4+ Consultation Grouper for 2022/23. This release is used to support the NHS England and Improvement consultation process for the 2022/23 National Tariff Payment System. In general, there are significant changes in base HRG design. A total of 120 new HRGs were created, multiple HRGs were removed, and the grouping logic was updated significantly. This Consultation Grouper will be superseded by the 2022/23 Local Payment Grouper in March 2022, for use from April 01, 2022.

In November 2021, the National Institute for Health Research (NIHR) in England released three MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned delivery for preterm birth, thoracolumbar fracture, and knee replacement. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

In early December 2021, NHS Accelerated Access Collaborative announced seven technologies that will be covered by the MedTech Funding Mandate (MTFM) in 2022/23: four for benign prostatic hyperplasia treatment (UroLift, GreenLight XPS, Rezum, and PLASMA system), and three for improving the patient experience during procedures (XprESS multi-sinus dilation system, Thopaz+, and Spectra Optia). Four technologies included in 2021/22 (placental growth factor-based testing, SecurAcath, HeartFlow, and gammaCore) will continue to be supported.

In November 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (percutaneous implantation of pulmonary artery pressure sensors in chronic heart failure and coronary sinus narrowing device implantation for refractory angina), one new Medical Technologies Guidance (Synergo for non-muscle-invasive bladder cancer), one new Diagnostic Guidance (SeHCAT for diagnosing bile acid diarrhea), and four new Medtech Innovation Briefings (clonoSEQ for minimal residual disease, CerebAir for continuous EEG monitoring, 24/7 EEG SubQ for epilepsy, Paige Prostate for prostate cancer). Also, three new clinical guidelines were published, and six were updated.

In November 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0180 and 0077 with changes to be implemented no later than February 01, 2022. Four new procedure codes related to neurology, spinal procedures, cancer pharmacotherapy, and ophthalmology, and three new diagnostic codes were introduced.

In October 2021, the Scottish Health Technology Group released two Innovative Medical Technology Overviews for e-health technologies. The topics were asynchronous digital dermatology appointment service (DDAS) and the Dxcover™ Brain Cancer Liquid Biopsy. Regarding DDAS, the authors concluded that the Scottish health boards should provide more data to allow for further performance and economic analyses of the DDAS. Regarding Dxcover™, the SHTG concluded that it was cost-effective, but further work to confirm its accuracy, effectiveness, safety, and cost-effectiveness is required.

In October 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (genicular artery embolization for pain from knee osteoarthritis, laparoscopic renal denervation for loin pain hematuria syndrome, percutaneous endovascular forearm arteriovenous fistula creation for hemodialysis access), and one new Medical Technologies Guidance (DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography). Also, two new clinical guidelines were published.

In November 2021, NHSX announced projects to improve digital pathways awarded for funding from the newly created Adoption Fund. Funding opportunities will support Integrated Care Systems (ICSs) with initiatives to test out digital pathways across various specialty areas, including gastroenterology, musculoskeletal, and cardiology. A total of 35 applications were successful and will share funding of £6.5 million.

In late September 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0179 and 0076 with changes to be implemented no later than January 01, 2022. Four new procedure codes related to gynecology, robotic surgery in the pulmonology area, and orthopedics, and four new diagnostic codes were introduced.

In October 2021, NHS England issued an updated version of the National Genomic Test Directory for 2021/2022, which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Twenty new codes (test-indication combinations) were introduced in the cancer field, and 115 new codes were added for rare and inherited diseases.